Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Catalent (NYSE:CTLT) Now Covered by StockNews.com
StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...
Catalent, Inc. (NYSE:CTLT) Receives $63.40 Consensus Target Price from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...
24/7 Wall St3h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Holdings says its acquisition of Catalent is complete.
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...
Lennox To Join S&P 500 Index, Replacing Catalent
Lennox International, an AI cooling play, will join the S&P 500 before the open on Dec. 23. Bill Holdings will take its place ...
Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Nordisk will take control of three fill-finish facilities of the contract drug manufacturer in Italy, Belgium, and the U ...
STAT18d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
The latest announcement is out from Catalent ( (CTLT) ).